Effects of Proprioceptive Focal Stimulation (EQUISTASI) on Freezing of Gait in Parkinson's Disease
- Conditions
- Freezing of GaitParkinson Disease
- Interventions
- Device: EQUISTASI
- Registration Number
- NCT03211260
- Lead Sponsor
- ASST Gaetano Pini-CTO
- Brief Summary
Freezing of gait (FOG) is a common disabling condition in Parkinson's disease (PD), causes falls, and impairs quality of life. Therapeutic options for this symptom are limited and of limited efficacy. Besides, the pathophysiology has been not clarified yet. Proprioceptive sensitivity is likely to play a role and recent studies have reported that high-frequency microfocal vibratory stimulation exert a modulatory effect of proprioceptive reflex circuits and could be considered a valuable treatment strategy. However, evidence is not available. The present study was designed to collect preliminary evidence of efficacy of a vibrotactile device (Equistasi) for the treatment of FOG.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 42
- Patient with Parkinson's Disease
- Stable drug therapy response without any change in the 3 months before the study.
- written informed consent
- Hoehn-Yahr stage ≥ 4
- Cognitive decline (Mini Mental State Examination <26)
- Systemic illness involving the nervous system
- Diabetes
- Presence of cardiac pacemaker
- Presence of deep brain stimulation
- Presence of severe dysautonomia with marked hypotension
- History or active neoplasia
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description EQUISTASI EQUISTASI Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
- Primary Outcome Measures
Name Time Method Freezing of gait questionnaire severity 4 weeks Change in freezing of gait questionnaire score
- Secondary Outcome Measures
Name Time Method 39-item Parkinson's Disease Questionnaire 4 weeks Change in quality of life measured using the 39-item Parkinson's Disease Questionnaire
Treatment continuation 4 weeks Likelihood that patients would continue taking the trial treatment as assessed by a self-rating scale
Falls 4 weeks Number of falls recorded during the intervention period
Gait and Falls Questionnaire (GFQ) score 4 weeks Change in the GFQ score
Trial Locations
- Locations (1)
Centro Parkinson, ASST Gaetano Pini-CTO
🇮🇹Milano, Italy